written on 06.06.2014

Boehringer scores European DVT/PE nod for market-trailer Pradaxa


In keeping with the FDA's recent approval, the European Commission has green-lighted Boehringer Ingelheim's clot-fighter Pradaxa to treat and prevent the recurrence of deep vein thrombrosis and pulmonary embolism, a nod that will boost Pradaxa as it battles it out in the anticoagulant market.